Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life
NCT06759077
·
clinicaltrials.gov ↗
PHASE3
Phase
ACTIVE_NOT_RECRUITING
Status
126
Enrollment
OTHER
Sponsor class
Conditions
Kidney Diseases
Interventions
DRUG:
Dapagliflozin (DAPA)
Sponsor
Al-Azhar University